We recently reported on the development of a novel series of BRAF inhibitors based on a tripartite A-B-C system characterized by a para-substituted central aromatic core connected to an imidazo[4,5]pyridin-2-one scaffold and a substituted urea linker. Here, we present a new series of BRAF inhibitors in which the central phenyl ring connects to the hinge binder and substrate pocket of BRAF with a meta-substitution pattern. The optimization of this new scaffold led to the development of lownanomolar inhibitors that permits the use of a wider range of linkers and terminal C rings while enhancing the selectivity for the BRAF enzyme in comparison to the para series. \ua9 2010 American Chemical Society
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of mela...
*S Supporting Information ABSTRACT: BET bromodomain inhibition has contributed new insights into gen...
<p>Chemical structures of studied BRAF inhibitors: (A) PLX4720, (B) Vemurafenib (B), PLX7904 (C) and...
We recently reported on the development of a novel series of BRAF inhibitors based on a tripartite A...
Mutated BRAF serine/threonine kinase is implicated in several types of cancer, with particularly hig...
BRAF, a serine/threonine specific protein kinase that is part of the MAPK pathway and acts as a down...
The RAS-RAF-MEK-ERK pathway is hyperactivated in 30% of human cancers. BRAF is a serine-threonine ki...
BRAF is a serine/threonine kinase that is mutated in a range of cancers, including 50-70% of melanom...
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of mela...
V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine-specific protein kinase ...
In this work, a new series of imidazo[2,1-b]thiazole was designed and synthesized. The new compounds...
ABSTRACT: Substitution mutations in the BRAF serine/threonine kinase are found in a variety of human...
We describe the synthesis and optimisation of a series of new inhibitors of BRAF, a kinase whose mut...
We describe the design, synthesis, and optimization of a series of new inhibitors of V-RAF murine sa...
BRAF V600E mutation has been detected in various malignant tumours. Developing of potent BRAF V600E ...
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of mela...
*S Supporting Information ABSTRACT: BET bromodomain inhibition has contributed new insights into gen...
<p>Chemical structures of studied BRAF inhibitors: (A) PLX4720, (B) Vemurafenib (B), PLX7904 (C) and...
We recently reported on the development of a novel series of BRAF inhibitors based on a tripartite A...
Mutated BRAF serine/threonine kinase is implicated in several types of cancer, with particularly hig...
BRAF, a serine/threonine specific protein kinase that is part of the MAPK pathway and acts as a down...
The RAS-RAF-MEK-ERK pathway is hyperactivated in 30% of human cancers. BRAF is a serine-threonine ki...
BRAF is a serine/threonine kinase that is mutated in a range of cancers, including 50-70% of melanom...
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of mela...
V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine-specific protein kinase ...
In this work, a new series of imidazo[2,1-b]thiazole was designed and synthesized. The new compounds...
ABSTRACT: Substitution mutations in the BRAF serine/threonine kinase are found in a variety of human...
We describe the synthesis and optimisation of a series of new inhibitors of BRAF, a kinase whose mut...
We describe the design, synthesis, and optimization of a series of new inhibitors of V-RAF murine sa...
BRAF V600E mutation has been detected in various malignant tumours. Developing of potent BRAF V600E ...
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of mela...
*S Supporting Information ABSTRACT: BET bromodomain inhibition has contributed new insights into gen...
<p>Chemical structures of studied BRAF inhibitors: (A) PLX4720, (B) Vemurafenib (B), PLX7904 (C) and...